Purpose: 130-nm albumin^bound paclitaxel (nab-paclitaxel) is a novel solvent-free albuminbound paclitaxel, designed to avoid solvent-related toxicity. Nab-paclitaxel has been successfully introduced into the clinic but its radiation-enhancing potential has not yet been evaluated. We conducted a preclinical evaluation of the radiation-modulating effects of nab-paclitaxel in tumor and normal tissues. Experimental Design: Mice bearing syngeneic ovarian or mammary carcinomas were treated with nab-paclitaxel, radiation, or combination of both. Nab-paclitaxel was administered at 90 mg/kg, 1.5 times the maximum tolerated dose for solvent-based paclitaxel. End points were antitumor efficacy (growth delay, radiocurability, and cellular effects) and normal tissue toxicity (gut and skin). Results: Nab-paclitaxel showed single-agent antitumor efficacy against both tumor types and acted as a radiosensitizer. Combined with radiation, nab-paclitaxel produced supra-additive effects when given before radiation. Nab-paclitaxel significantly increased radiocurability by reducing the dose yielding 50% tumor cure (TCD 50 ) from 54.3 to 35.2 Gy. Tumor histology following nab-paclitaxel treatment was characterized by pronounced necrotic and apoptotic cell death and mitotic arrest. Nab-paclitaxel did not increase normal tissue radioresponse. Conclusions: Nab-paclitaxel exhibited strong antitumor efficacy against both tumors as a single agent and it improved radiotherapy in a supra-additive manner. These improved effects were achieved without increased normal tissue toxicity to either rapidly or slowly proliferating normal tissues although the drug dose was 1.5 times higher than the maximum tolerated dose of solventbased paclitaxel. These preclinical findings show that combining nab-paclitaxel with radiotherapy would improve the outcome of taxane-based chemoradiotherapy. This novel taxane is thus a good candidate for testing in clinical chemoradiotherapy trials.Besides being very efficient cytotoxic drugs on their own, taxanes are also potent enhancers of tumor radiation response. In the clinical setting, taxanes are being used as radiationenhancing drugs in a variety of disease sites including nonsmall-cell lung cancer, head and neck, esophageal, gastric, cervical, urothelial, and nasopharyngeal carcinoma (1 -7).Taxanes are complex diterpenoids characterized by an extremely hydrophobic structure with sparse aqueous solubility (8). To overcome solubility problems, chemical solvents such as ethanol, Tween 80, and castor oil (Cremophor EL) are used in currently approved solvent-based taxane formulations. These solvents are known to cause biological and pharmacologic side effects, including dose-limiting toxicity, acute hypersensitivity reactions, and altered pharmacokinetics (resulting in a nonlinear pharmacokinetic profile). As a result, intensive research is being aimed at developing alternative formulations (8 -12).One such alternative is nab-paclitaxel (Abraxane), a novel, solvent-free 130-nm nanoparticle albumin -bound formu...